- Home
- PVL vs EDSA Comparison
PVL vs EDSA Comparison
Compare PVL & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PVL | EDSA |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1M | 51.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PVL | EDSA |
|---|---|---|
| Price | $1.84 | $4.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 60.4K | ★ 75.9K |
| Earning Date | 03-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.43% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.85 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.58 | $0.72 |
| 52 Week High | $2.04 | $20.32 |
Technical Indicators
Market Signals| Indicator | PVL | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 43.44 |
| Support Level | $1.73 | $4.69 |
| Resistance Level | $1.92 | $6.62 |
| Average True Range (ATR) | 0.04 | 0.61 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 64.36 | 27.84 |
Price Performance
Historical ComparisonAbout PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.